Banagan, Reymark .

HRN: 27-39-01  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/25/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
06/25/2025
07/02/2025
IV
2.25gms
Q6
Septic Shock
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Bloodstream    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: